Disease activity was mild in 42.5%, moderate in 32.9% and severe in 21.3% of the patients. The mean CSI was 38.4 (SD: 18.7) and thirty-four (46.5%) of 73 patients had CS according to the CSI. CSI scores were significantly higher in females than in males (p=0.009). Eleven (15%) patients had coexisting resistance, and those with coexisting resistance had significantly higher CS scores. In patients with central sensitization, PRAS, HAQ FMF-QoL, FiRST, PSQI, and HADS scores were significantly higher than in patients without central sensitization (Table 1).

Conclusion: CS is present in approximately half of FMF patients, CS in patients with FMF is associated with high disease activity, fibromyalgia, anxiety, depression, impaired function, poor quality of life and sleep.

REFERENCES:

Disclosure of Interests: None declared